Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer

KRAS and TP53 mutations, which are the most common genetic drivers of tumorigenesis, are still considered undruggable targets. Therefore, we analyzed these genetic aberrations in metastatic non-small cell lung cancer (NSCLC) for the development of potential therapeutics. One hundred eighty-five cons...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Wang, Yudong, Wang, Zhijie, Piha-Paul, Sarina, Janku, Filip, Subbiah, Vivek, Shi, Naiyi, Hess, Kenneth, Broaddus, Russell, Shan, Baoen, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Lu, Charles, Papadimitrakopoulou, Vali, Heymach, John, Meric-Bernstam, Funda, Fu, Siqing
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6161801/
https://ncbi.nlm.nih.gov/pubmed/30279957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25947
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados